Cargando…
Efficacy and safety of bipolar androgen therapy in castration-resistant prostate cancer following abiraterone or enzalutamide resistance: A systematic review
Bipolar androgen therapy (BAT) is a new endocrinologic treatment for castration-resistant prostate cancer (CRPC) that can restore some patients’ sensitivity to drugs such as abiraterone (Abi) and enzalutamide (Enz). We performed a meta-analysis using STATA16. Sensitivity analyses were performed by e...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10127253/ https://www.ncbi.nlm.nih.gov/pubmed/37113653 http://dx.doi.org/10.3389/fendo.2022.1125838 |
_version_ | 1785030424666308608 |
---|---|
author | You, Xiangyun Huang, Shan Wang, Xin’an Yi, Cheng Gong, Niandong Yu, Junfeng Xu, Chengdang Xiang, Zhendong |
author_facet | You, Xiangyun Huang, Shan Wang, Xin’an Yi, Cheng Gong, Niandong Yu, Junfeng Xu, Chengdang Xiang, Zhendong |
author_sort | You, Xiangyun |
collection | PubMed |
description | Bipolar androgen therapy (BAT) is a new endocrinologic treatment for castration-resistant prostate cancer (CRPC) that can restore some patients’ sensitivity to drugs such as abiraterone (Abi) and enzalutamide (Enz). We performed a meta-analysis using STATA16. Sensitivity analyses were performed by examining the effects of individual studies using different effect models and detecting any publication bias using the Harbord test. In a total of 108 unique records, ten studies were included in the final meta-analysis. Participants who underwent BAT achieved a PSA50 response rate of 27% (95%CI [0.22,0.31], I2=17.98%), ORR of 34% (95%CI [0.24,0.43], I2=0), and incidence of AEs (grade≥3) of 14% (95%CI [0.09,0.19], I2=0). Patients who completed BAT proceeded to AR-targeted therapy (Abi or Enz) and achieved a PSA50 response rate of 57% (95% CI [0.36,0.78], I2=0). Patients with prior Enz resistance had a stronger impact on the PSA50 of AR-target therapy rechallenge. The results of this meta-analysis indicate that BAT is a safe and effective treatment for patients who have progressed after Abi or Enz. BAT can trigger the resensitization of patients with CRPC to subsequent endocrine therapy and improve the overall survival of patients and their quality of life. |
format | Online Article Text |
id | pubmed-10127253 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-101272532023-04-26 Efficacy and safety of bipolar androgen therapy in castration-resistant prostate cancer following abiraterone or enzalutamide resistance: A systematic review You, Xiangyun Huang, Shan Wang, Xin’an Yi, Cheng Gong, Niandong Yu, Junfeng Xu, Chengdang Xiang, Zhendong Front Endocrinol (Lausanne) Endocrinology Bipolar androgen therapy (BAT) is a new endocrinologic treatment for castration-resistant prostate cancer (CRPC) that can restore some patients’ sensitivity to drugs such as abiraterone (Abi) and enzalutamide (Enz). We performed a meta-analysis using STATA16. Sensitivity analyses were performed by examining the effects of individual studies using different effect models and detecting any publication bias using the Harbord test. In a total of 108 unique records, ten studies were included in the final meta-analysis. Participants who underwent BAT achieved a PSA50 response rate of 27% (95%CI [0.22,0.31], I2=17.98%), ORR of 34% (95%CI [0.24,0.43], I2=0), and incidence of AEs (grade≥3) of 14% (95%CI [0.09,0.19], I2=0). Patients who completed BAT proceeded to AR-targeted therapy (Abi or Enz) and achieved a PSA50 response rate of 57% (95% CI [0.36,0.78], I2=0). Patients with prior Enz resistance had a stronger impact on the PSA50 of AR-target therapy rechallenge. The results of this meta-analysis indicate that BAT is a safe and effective treatment for patients who have progressed after Abi or Enz. BAT can trigger the resensitization of patients with CRPC to subsequent endocrine therapy and improve the overall survival of patients and their quality of life. Frontiers Media S.A. 2023-04-11 /pmc/articles/PMC10127253/ /pubmed/37113653 http://dx.doi.org/10.3389/fendo.2022.1125838 Text en Copyright © 2023 You, Huang, Wang, Yi, Gong, Yu, Xu and Xiang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Endocrinology You, Xiangyun Huang, Shan Wang, Xin’an Yi, Cheng Gong, Niandong Yu, Junfeng Xu, Chengdang Xiang, Zhendong Efficacy and safety of bipolar androgen therapy in castration-resistant prostate cancer following abiraterone or enzalutamide resistance: A systematic review |
title | Efficacy and safety of bipolar androgen therapy in castration-resistant prostate cancer following abiraterone or enzalutamide resistance: A systematic review |
title_full | Efficacy and safety of bipolar androgen therapy in castration-resistant prostate cancer following abiraterone or enzalutamide resistance: A systematic review |
title_fullStr | Efficacy and safety of bipolar androgen therapy in castration-resistant prostate cancer following abiraterone or enzalutamide resistance: A systematic review |
title_full_unstemmed | Efficacy and safety of bipolar androgen therapy in castration-resistant prostate cancer following abiraterone or enzalutamide resistance: A systematic review |
title_short | Efficacy and safety of bipolar androgen therapy in castration-resistant prostate cancer following abiraterone or enzalutamide resistance: A systematic review |
title_sort | efficacy and safety of bipolar androgen therapy in castration-resistant prostate cancer following abiraterone or enzalutamide resistance: a systematic review |
topic | Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10127253/ https://www.ncbi.nlm.nih.gov/pubmed/37113653 http://dx.doi.org/10.3389/fendo.2022.1125838 |
work_keys_str_mv | AT youxiangyun efficacyandsafetyofbipolarandrogentherapyincastrationresistantprostatecancerfollowingabirateroneorenzalutamideresistanceasystematicreview AT huangshan efficacyandsafetyofbipolarandrogentherapyincastrationresistantprostatecancerfollowingabirateroneorenzalutamideresistanceasystematicreview AT wangxinan efficacyandsafetyofbipolarandrogentherapyincastrationresistantprostatecancerfollowingabirateroneorenzalutamideresistanceasystematicreview AT yicheng efficacyandsafetyofbipolarandrogentherapyincastrationresistantprostatecancerfollowingabirateroneorenzalutamideresistanceasystematicreview AT gongniandong efficacyandsafetyofbipolarandrogentherapyincastrationresistantprostatecancerfollowingabirateroneorenzalutamideresistanceasystematicreview AT yujunfeng efficacyandsafetyofbipolarandrogentherapyincastrationresistantprostatecancerfollowingabirateroneorenzalutamideresistanceasystematicreview AT xuchengdang efficacyandsafetyofbipolarandrogentherapyincastrationresistantprostatecancerfollowingabirateroneorenzalutamideresistanceasystematicreview AT xiangzhendong efficacyandsafetyofbipolarandrogentherapyincastrationresistantprostatecancerfollowingabirateroneorenzalutamideresistanceasystematicreview |